Literature DB >> 15781169

Renal replacement therapy III: IHD, CRRT, SLED.

Philip O'Reilly1, Ashita Tolwani.   

Abstract

Acute renal failure in critically ill patients is a growing clinical problem. Options for renal replacement therapy in these patients use convective and diffusive clearance and may be intermittent, as in classic hemodialysis, or continuous. New ways of delivering dialysis in the intensive care unit, such as sustained low-efficiency dialysis, are also under development. It may be that renal replacement therapy needs to be tailored to the needs of each individual patient. Current and future research studies should provide the answers to many of these questions.

Entities:  

Mesh:

Year:  2005        PMID: 15781169     DOI: 10.1016/j.ccc.2005.01.004

Source DB:  PubMed          Journal:  Crit Care Clin        ISSN: 0749-0704            Impact factor:   3.598


  4 in total

1.  Dosing nucleoside reverse transcriptase inhibitors in adults receiving continuous veno-venous hemofiltration.

Authors:  Milena M McLaughlin; Abeer T Ammar; Lana Gerzenshtein; Kimberly K Scarsi
Journal:  Clin Drug Investig       Date:  2015-04       Impact factor: 2.859

2.  Treatment of critically ill children with kidney injury by sustained low-efficiency daily diafiltration.

Authors:  Chia-Ying Lee; Huang-Chieh Yeh; Ching-Yuang Lin
Journal:  Pediatr Nephrol       Date:  2012-08-18       Impact factor: 3.714

3.  Effect of continuous venovenous hemofiltration dose on achievement of adequate vancomycin trough concentrations.

Authors:  Erin N Frazee; Philip J Kuper; Garrett E Schramm; Scott L Larson; Kianoush B Kashani; Douglas R Osmon; Nelson Leung
Journal:  Antimicrob Agents Chemother       Date:  2012-09-17       Impact factor: 5.191

4.  Diagnostics, Risk Factors, Treatment and Outcomes of Acute Kidney Injury in a New Paradigm.

Authors:  Charat Thongprayoon; Panupong Hansrivijit; Karthik Kovvuru; Swetha R Kanduri; Aldo Torres-Ortiz; Prakrati Acharya; Maria L Gonzalez-Suarez; Wisit Kaewput; Tarun Bathini; Wisit Cheungpasitporn
Journal:  J Clin Med       Date:  2020-04-13       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.